Shen, Lin

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet

Gastric Cancer Management and OutcomesHER2/EGFR in Cancer Research

Cited by 7,302

Granzyme A from cytotoxic lymphocytes cleaves GSDMB to trigger pyroptosis in target cells

Zhou, Z., He, H., Wang, K., Shi, X., Wang, Y., Su, Y., Wang, Y., Li, D., Liu, W., Zhang, Y., et al. (2020) · Science

Inflammasome and immune disordersCell death mechanisms and regulation

Cited by 1,317

Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial

Li, J., Qin, S., Xu, R.-H., Shen, L., Xu, J., Bai, Y., Yang, L., Deng, Y., Chen, Z.-D., Zhong, H., et al. (2018) · JAMA

Colorectal Cancer Treatments and StudiesAngiogenesis and VEGF in Cancer

Cited by 425

The Gut Microbiome Is Associated with Clinical Response to Anti–PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer

Peng, Z., Cheng, S., Kou, Y., Wang, Z., Jin, R., Hu, H., Zhang, X., Gong, J.-F., Li, J., Lu, M., et al. (2020) · Cancer Immunology Research

Gut microbiota and healthCancer Immunotherapy and Biomarkers

Cited by 361

LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study

Moehler, M., Shitara, K., Garrido, M., Salman, P., Shen, L., Wyrwicz, L., Yamaguchi, K., Skoczylas, T., Campos Bragagnoli, A., Liu, T., et al. (2020) · Annals of Oncology

Gastric Cancer Management and OutcomesCancer Immunotherapy and Biomarkers

Cited by 208

Molecular mechanisms underlying the resistance of BRAF V600E-mutant metastatic colorectal cancer to EGFR/BRAF inhibitors

Xu, T., Wang, X., Wang, Z., Deng, T., Qi, C., Liu, D., Li, Y., Ji, C., Li, J., & Shen, L. (2022) · Therapeutic Advances in Medical Oncology

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 38

Characteristics and Prognosis of Acquired Resistance to Immune Checkpoint Inhibitors in Gastrointestinal Cancer

Zhuo, N., Liu, C., Zhang, Q., Li, J., Zhang, X., Gong, J., Lu, M., Peng, Z., Zhou, J., Wang, X., et al. (2022) · JAMA Network Open

Cancer Immunotherapy and BiomarkersColorectal Cancer Treatments and Studies

Cited by 30

Real‐world treatment and outcomes of patients with metastatic BRAF mutant colorectal cancer

Xu, T., Li, J., Wang, Z., Zhang, X., Zhou, J., Lu, Z., Shen, L., & Wang, X. (2023) · Cancer Medicine

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 20

Phase 1 study of SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with advanced solid tumors.

Liu, D., Gong, J., Liu, T., Li, K., Yin, X., Liu, Y., Wang, Y., Wang, L., Wang, W., Zhang, Y., et al. (2021) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersTGF-β signaling in diseases

Cited by 16

Promising early results of MHB088C (B7-H3 ADC) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) from a phase 1/2 multicenter study.

Shen, L., Meng, X., Sun, Y., Zhao, Y., Huang, H., Han, L., Zhang, Z., Chang, F., Ji, Y., Wu, G., et al. (2025) · Journal of Clinical Oncology

Prostate Cancer Treatment and ResearchProtein Degradation and Inhibitors

Cited by 4